12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Archexin: Phase IIa data

Top-line data from a single-arm, open-label, U.S. and Indian Phase IIa trial in 31 patients aged 18-65 with metastatic pancreatic cancer showed that Archexin plus gemcitabine led to a median OS, the primary endpoint, of 9.1 months vs. 5.7 months for a historical control...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >